文献速递产科母胎医学

基于19-24周生物物理与生化标志物风险分层管理子痫前期

Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-07-28

这项前瞻性非干预研究纳入37 886例单胎孕妇,在19-24周联合母体因素、UtA-PI、MAP、PlGF和sFlt-1计算子痫前期风险。加入PlGF和sFlt-1可提高早产子痫前期筛查效能,但对≥36周子痫前期预测效果差。

要点

  • 19-24周联合母体因素、UtA-PI、MAP、PlGF和sFlt-1可优化早产子痫前期风险分层。
  • 筛查早产子痫前期时,加入PlGF和sFlt-1可降低假阳性率。
  • 现有方法对≥36周子痫前期预测效能均较差。

核心结论

  • 在19-24周,联合母体因素、UtA-PI和MAP筛查早产子痫前期的基础上加入PlGF和sFlt-1可提高筛查效能。
  • 对≥36周子痫前期的预测,无论采用哪种筛查方法,效能均较差。

研究设计与样本

  • 前瞻性非干预研究,纳入37 886例单胎孕妇,在19-24周进行超声检查时计算子痫前期风险。

主要发现

  • 研究人群中1130例(3.0%)发生子痫前期,其中160例(0.4%)在<36周分娩。
  • 以检出约90%的<28、<32和<36周子痫前期为目标,母体因素+UtA-PI+MAP的假阳性率分别为3.1%、8.5%和19.1%。
  • 加入PlGF后,相应假阳性率降至0.2%、0.7%和10.6%;再加入sFlt-1后降至0.1%、0.4%和9.5%。
  • 在10%假阳性率下,三种方法对≥36周子痫前期的检出率范围为33.2%至38.4%。

临床怎么用

  • 可在19-24周联合母体因素、UtA-PI、MAP、PlGF和sFlt-1评估早产子痫前期风险,用于风险分层管理。
  • 对≥36周子痫前期,19-24周的上述筛查方法预测效能有限,需谨慎解读。

局限性

  • 本研究为非干预研究,筛查效能基于模型预测和 empirical 结果,未报告干预效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We have proposed previously that all pregnant women should have assessment of risk for pre-eclampsia (PE) at 20 and 36 weeks' gestation and that the 20-week assessment should be used to define subgroups requiring additional monitoring and reassessment at 28 and 32 weeks. The objective of this study was to examine the potential improvement in screening at 19-24 weeks' gestation for PE with delivery at < 28, < 32, < 36 and ≥ 36 weeks' gestation by the addition of serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) to the combination of maternal demographic characteristics and medical history, uterine artery pulsatility index (UtA-PI) and mean arterial pressure (MAP). METHODS: This was a prospective, non-intervention study in women attending for an ultrasound scan at 19-24 weeks as part of routine pregnancy care. Patient-specific risks of delivery with PE at < 36 weeks' gestation were calculated using the competing-risks model to combine the prior distribution of gestational age at delivery with PE, obtained from maternal characteristics and medical history, with multiples of the median values of UtA-PI, MAP, PlGF and sFlt-1. Different risk cut-offs were used to vary the proportion of the population stratified into each of four risk categories (very high risk, high risk, intermediate risk and low risk) with the intention of detecting about 80%, 85%, 90% and 95% of cases of delivery with PE at < 28, < 32 and < 36 weeks' gestation. The performance of screening was assessed by plotting the detection rate against the screen-positive rate and calculating the areas under these curves, and by the proportion stratified into a given group for fixed detection rates. Model-based estimates of screening performance for these various combinations of markers were also produced. RESULTS: In the study population of 37 886 singleton pregnancies, there were 1130 (3.0%) that subsequently developed PE, including 160 (0.4%) that delivered at < 36 weeks' gestation. In both the modeled and empirical results, there was incremental improvement in the performance of screening with the addition of PlGF and sFlt-1 to the combination of maternal factors, UtA-PI and MAP. If the objective of screening was to identify about 90% of cases of PE with delivery at < 28, < 32 and < 36 weeks and the method of screening was a combination of maternal factors, UtA-PI and MAP, the respective screen-positive rates would be 3.1%, 8.5% and 19.1%. The respective values for screening by maternal factors, UtA-PI, MAP and PlGF were 0.2%, 0.7% and 10.6%, and for screening by maternal factors, UtA-PI, MAP, PlGF and sFlt-1 they were 0.1%, 0.4% and 9.5%. The empirical results were consistent with the modeled results. There was good agreement between the predicted risk and the observed incidence of PE at < 36 weeks' gestation for all three strategies of screening. Prediction of PE at ≥ 36 weeks was poor for all three screening methods, with the detection rate, at a 10% screen-positive rate, ranging from 33.2% to 38.4%. CONCLUSIONS: The performance of screening at 19-24 weeks' gestation for PE with delivery at < 28, < 32 and < 36 weeks' gestation achieved by a combination of maternal demographic characteristics and medical history, UtA-PI and MAP is improved by the addition of serum PlGF and sFlt-1. The performance of screening for PE at ≥ 36 weeks' gestation is poor irrespective of the method of screening at 19-24 weeks. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Litwinska M, Litwinska E, Astudillo A, et al. Stratification of pregnancy care based on risk of pre-eclampsia derived from biophysical and biochemical markers at 19-24 weeks' gestation. Ultrasound Obstet Gynecol. 2021. PMID: 33794058. doi:10.1002/uog.23640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。